Marion Watson
A5016533291- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Fungal and yeast genetics research
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- RNA and protein synthesis mechanisms
- Autoimmune and Inflammatory Disorders Research
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Health Systems, Economic Evaluations, Quality of Life
- Plant Disease Resistance and Genetics
- Osteoarthritis Treatment and Mechanisms
- Biofuel production and bioconversion
- Virus-based gene therapy research
- Machine Learning in Bioinformatics
- Studies on Chitinases and Chitosanases
- Bacterial Genetics and Biotechnology
- HIV/AIDS drug development and treatment
- Kawasaki Disease and Coronary Complications
- Agricultural Science and Fertilization
- Vaccine Coverage and Hesitancy
- Agronomic Practices and Intercropping Systems
- Transgenic Plants and Applications
Nuffield Orthopaedic Centre
2021-2024
University of Oxford
2020-2024
Jenner Institute
2020-2024
Oxford Research Group
1989
Wycombe General Hospital
1984
SummaryBackgroundA safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of COVID-19 pandemic. We evaluated safety efficacy ChAdOx1 nCoV-19 in a pooled interim analysis four trials.MethodsThis includes data from ongoing blinded, randomised, controlled trials done across UK, Brazil, South Africa. Participants aged 18 years older were randomly assigned (1:1) or (meningococcal group A,...
Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity vaccines is often worse in older as result immunosenescence. We have reported the immunogenicity novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), young adults, now describe safety this wider range participants, including aged 70 years older.In report phase 2 component...
Abstract The effect of sulphur fertilisation on yield and herbage composition was investigated in two successive years at grassland sites, one with ryegrass ryegrass/ clover, where the available soil less than 10 mg kg − 1. When supplies N, P K were not limiting, yields increased added both particularly second third cuts year. Sulphur additions also concentrations total S SO 4 2−S crop, reduced N:S ratio. figures for these parameters from control plots confirmed that low presence normal...
Abstract Background The Tight Control of psoriatic arthritis (TICOPA) trial confirmed improved clinical outcomes with a treat to target (T2T) strategy in (PsA). This consisted 4-weekly review and escalation ‘step up’ therapy (single disease modifying (DMARD), combination DMARDs then biologics) based on remission criteria. Based this, T2T approach is supported by European PsA treatment recommendations. However, it not commonly implemented routine care primarily due feasibility cost concerns....
A synthetic gene coding for human interleukin 4 (IL-4) was cloned and expressed in Saccharomyces cerevisiae (baker's yeast) as a C-terminal fusion protein with the yeast prepro alpha-mating factor sequence, resulting secretion of mature IL-4 into culture medium (0.6-0.8 micrograms/ml). protocol developed purification this protein. Crude cell-free conditioned passed over concanavalin A-Sepharose affinity column; bound proteins were eluted further purified by S-Sepharose Fast Flow cation...
The aim of the Severe Psoriatic arthritis - Early intervEntion to control Disease trial is compare outcomes in psoriatic (PsA) patients with poor prognostic factors treated standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), combination csDMARDs or a course early biologics.
In psoriatic arthritis (PsA), treatment recommendations support first-line use of disease-modifying antirheumatic drugs (DMARDs). There are few strategy trials, and no previous studies have investigated tailored choice by disease severity. Studies in oligoarthritis (<5 inflamed joints) limited but suggested that some can be managed without DMARDs, preventing unnecessary side effects. This study aimed to assess the feasibility acceptability a comparing standard DMARD against symptomatic...
Hand osteoarthritis (OA) is a common condition, causing pain, stiffness and reduced quality of life. Incidence higher amongst women, particularly around the age menopause. Whilst relationship between sex hormones OA has been studied in vitro, epidemiological studies clinical trials hormone replacement therapy (HRT), this study first to investigate effect estrogen-containing on hand pain post-menopausal women with symptomatic randomised design.This feasibility double-blinded...
Abstract BackgroundThe Tight Control of psoriatic arthritis (TICOPA) trial confirmed improved clinical outcomes with a treat to target (T2T) strategy in PsA. This consisted 4-weekly review and escalation ‘step up’ therapy (single disease modifying (DMARD), combination DMARDs then biologics) based on remission criteria. Based this, T2T approach is supported by European PsA treatment recommendations. However, it not commonly implemented routine care primarily due feasibility cost concerns. In...